<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149875</url>
  </required_header>
  <id_info>
    <org_study_id>605872</org_study_id>
    <nct_id>NCT02149875</nct_id>
  </id_info>
  <brief_title>Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke</brief_title>
  <official_title>A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 6th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12
      hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a
      10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National
      Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the
      efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were
      also analyzed among the three groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale Score</measure>
    <time_frame>At 11-day and 21-day after therapy</time_frame>
    <description>Scores range from 0 to 42, with higher scores indicating increasing severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barthel Index Score</measure>
    <time_frame>At 11-day and 21-day after therapy</time_frame>
    <description>Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Acute Cerebral Stroke Within 12 Hours for the First Time</condition>
  <arm_group>
    <arm_group_label>Dl-3-n-butylphthalide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dl-3-n-butylphthalide</intervention_name>
    <description>Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.</description>
    <arm_group_label>Dl-3-n-butylphthalide</arm_group_label>
    <other_name>CSPC NBP Pharmaceutical Co., Ltd., Shijiazhuang, China</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin</intervention_name>
    <description>Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.</description>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <other_name>Ever Pharma, Unterach am Attersee, Austria</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 ml saline intravenous infusion once daily for 10 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Hebei Tiancheng Pharmaceutical Co., Ltd., Cangzhou, China</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ischemic stroke within 12 hours for the first time before entry into the study

          -  National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25

        Exclusion Criteria:

          -  with lacunar infarction

          -  with cerebral hemorrhagic infarction

          -  with epilepsy or epileptic persons

          -  with history of neurological diseases

          -  with myocardial infarction,

          -  with renal and hepatic abnormalities

          -  with metabolic diseases

          -  with contraindications to antiplatelet treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Chen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 6th People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <results_first_submitted>April 12, 2016</results_first_submitted>
  <results_first_submitted_qc>April 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 18, 2016</results_first_posted>
  <last_update_submitted>May 18, 2016</last_update_submitted>
  <last_update_submitted_qc>May 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 6th People's Hospital</investigator_affiliation>
    <investigator_full_name>Hao Chen</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Dl-3-n-butylphthalide</keyword>
  <keyword>Cerebrolysin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrolysin</mesh_term>
    <mesh_term>3-n-butylphthalide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From January 2010 to May 2010, a randomized, double‑blind trial was conducted, which involved patients with AIS in the Neurology Ward of Shanghai Jiao Tong University Affiliated Sixth People's Hospital (Shanghai, China).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dl-3-n-butylphthalide</title>
          <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
&quot;Dl-3-n-butylphthalide&quot;, &quot;Cerebrolysin&quot; and &quot;Placebo&quot; separately</description>
        </group>
        <group group_id="P2">
          <title>Cerebrolysin</title>
          <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
&quot;Dl-3-n-butylphthalide&quot;, &quot;Cerebrolysin&quot; and &quot;Placebo&quot; separately</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days
&quot;Dl-3-n-butylphthalide&quot;, &quot;Cerebrolysin&quot; and &quot;Placebo&quot; separately</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dl-3-n-butylphthalide</title>
          <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days.</description>
        </group>
        <group group_id="B2">
          <title>Cerebrolysin</title>
          <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="6.3"/>
                    <measurement group_id="B2" value="66.5" spread="8.1"/>
                    <measurement group_id="B3" value="68.4" spread="4.2"/>
                    <measurement group_id="B4" value="67.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time until admission</title>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="3.0"/>
                    <measurement group_id="B2" value="5.0" spread="3.3"/>
                    <measurement group_id="B3" value="4.8" spread="3.7"/>
                    <measurement group_id="B4" value="5.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time until treatment</title>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="5.9"/>
                    <measurement group_id="B2" value="7.6" spread="3.6"/>
                    <measurement group_id="B3" value="5.6" spread="3.0"/>
                    <measurement group_id="B4" value="7.0" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148.6" spread="14.6"/>
                    <measurement group_id="B2" value="150.7" spread="13.7"/>
                    <measurement group_id="B3" value="152.5" spread="12.8"/>
                    <measurement group_id="B4" value="150.6" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.7" spread="10.7"/>
                    <measurement group_id="B2" value="85.1" spread="13.6"/>
                    <measurement group_id="B3" value="87.2" spread="12.5"/>
                    <measurement group_id="B4" value="87.0" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>National Institutes of Health Stroke Scale score</title>
          <description>The scores range from 0 to 42, with higher scores indicating increasing severity. A score of &lt; 4 represented low-degree impairment, between 4 and 15 represented medium-degree impairment, and a score of &gt; 15 represented severe-degree impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" spread="4.38"/>
                    <measurement group_id="B2" value="10.6" spread="4.74"/>
                    <measurement group_id="B3" value="10.2" spread="3.72"/>
                    <measurement group_id="B4" value="11.1" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Barthel Index score</title>
          <description>The scores range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.75" spread="6.38"/>
                    <measurement group_id="B2" value="22.25" spread="7.16"/>
                    <measurement group_id="B3" value="22.00" spread="6.96"/>
                    <measurement group_id="B4" value="21.33" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>National Institutes of Health Stroke Scale Score</title>
        <description>Scores range from 0 to 42, with higher scores indicating increasing severity</description>
        <time_frame>At 11-day and 21-day after therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dl-3-n-butylphthalide</title>
            <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Cerebrolysin</title>
            <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>National Institutes of Health Stroke Scale Score</title>
          <description>Scores range from 0 to 42, with higher scores indicating increasing severity</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.78" spread="2.48"/>
                    <measurement group_id="O2" value="7.80" spread="5.81"/>
                    <measurement group_id="O3" value="8.85" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" spread="2.34"/>
                    <measurement group_id="O2" value="5.90" spread="3.96"/>
                    <measurement group_id="O3" value="7.30" spread="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Barthel Index Score</title>
        <description>Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence</description>
        <time_frame>At 11-day and 21-day after therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dl-3-n-butylphthalide</title>
            <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Cerebrolysin</title>
            <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Barthel Index Score</title>
          <description>Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.25" spread="10.57"/>
                    <measurement group_id="O2" value="36.00" spread="10.81"/>
                    <measurement group_id="O3" value="31.00" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.00" spread="14.01"/>
                    <measurement group_id="O2" value="53.75" spread="13.10"/>
                    <measurement group_id="O3" value="43.75" spread="15.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days</time_frame>
      <desc>Systematic methods include a physical examination (including heart rate, blood pressure and oxygen concentration), laboratory tests (including urine test, complete blood count, occult blood test, renal function, liver function, electrolyte and blood‑glucose), electrocardiogram, cranial CT or MRI and chest radiograph.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dl-3-n-butylphthalide</title>
          <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days.</description>
        </group>
        <group group_id="E2">
          <title>Cerebrolysin</title>
          <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>TESS</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation disorder</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>TESS</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Foremost is the relatively small sample size, and only patients with moderate severity of stroke were enrolled, so the efficacy results of this study should be interpreted with caution.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Hao Chen</name_or_title>
      <organization>Shanghai Sixth People's Hospital</organization>
      <phone>02164369181 ext 8405</phone>
      <email>chenhao_316@aliyun.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

